Article

You have full text access to this OnlineOpen article

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases†

  1. Douglas J. Marcotte1,
  2. Yu-Ting Liu1,
  3. Robert M. Arduini1,
  4. Catherine A. Hession1,
  5. Konrad Miatkowski1,
  6. Craig P. Wildes1,
  7. Patrick F. Cullen1,
  8. Victor Hong1,
  9. Brian T. Hopkins1,
  10. Elisabeth Mertsching2,
  11. Tracy J. Jenkins1,
  12. Michael J. Romanowski3,‡,
  13. Darren P. Baker1,
  14. Laura F. Silvian1,*

Article first published online: 5 JAN 2010

DOI: 10.1002/pro.321

Issue

Protein Science

Protein Science

Volume 19, Issue 3, pages 429–439, March 2010

Additional Information

How to Cite

Marcotte, D. J., Liu, Y.-T., Arduini, R. M., Hession, C. A., Miatkowski, K., Wildes, C. P., Cullen, P. F., Hong, V., Hopkins, B. T., Mertsching, E., Jenkins, T. J., Romanowski, M. J., Baker, D. P. and Silvian, L. F. (2010), Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Science, 19: 429–439. doi: 10.1002/pro.321

Author Information

  1. 1

    Biogen Idec, Inc., Drug Discovery Department, 12 Cambridge Center, Cambridge, Massachusetts 02142

  2. 2

    Biogen Idec, Inc., 5200 Research Place, San Diego, California 92122

  3. 3

    Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard, South San Francisco, California 94080

  1. ‡

    Novartis Institutes for Biomedical Research, Cambridge, MA 02139

*Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA 02142

  1. †

    Disclosure: All authors (with the exception of M. J. Romanowski) are employees of Biogen Idec and own company stock.

Publication History

  1. Issue published online: 22 FEB 2010
  2. Article first published online: 5 JAN 2010
  3. Manuscript Accepted: 14 DEC 2009
  4. Manuscript Revised: 11 DEC 2009
  5. Manuscript Received: 12 OCT 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (497K)

References

  • 1
    Kurosaki T, Kurosaki M ( 1997) Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. J Biol Chem 272: 15595–15598.
  • 2
    Tsukada S, Witte ON ( 1994) X-linked agammaglobulinemia and Bruton's tyrosine kinase. Adv Exp Med Biol 365: 233–238.
  • 3
    Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarström L, Kinnon C, Levinsky R, Bobrow M, Smith CIE, Bentley DR ( 1993) The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361: 226–233.
  • 4
    Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, Uckun FM ( 1999) Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide]. J Biol Chem 274: 9587–9599.
  • 5
    van den Akker E, van Dijk TB, Schmidt U, Felida L, Beug H, Lowenberg B, von Lindern M ( 2004) The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem 385: 409–413.
  • 6
    Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH ( 2007) Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 15: 800–814.
  • 7
    Mao C, Zhou M, Uckun FM ( 2001) Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem 276: 41435–41443.
  • 8
    Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G ( 2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104: 13283–13288.
  • 9
    Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, III, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ ( 2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011–11016.
  • 10
    Arnold LD, Calderwood DJ, Dixon RW, Johnston DN, Kamens JS, Munschauer R, Rafferty P, Ratnofsky SE ( 2000) Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck. Bioorg Med Chem Lett 10: 2167–2170.
  • 11
    Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT ( 2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2: 58–61.
    Direct Link:
  • 12
    Calderwood DJ, Johnston DN, Munschauer R, Rafferty P ( 2002) Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorg Med Chem Lett 12: 1683–1686.
  • 13
    Valiaho J, Smith CI, Vihinen M ( 2006) BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat 27: 1209–1217.
    Direct Link:
  • 14
    Brown K, Long JM, Vial SC, Dedi N, Dunster NJ, Renwick SB, Tanner AJ, Frantz JD, Fleming MA, Cheetham GM ( 2004) Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors. J Biol Chem 279: 18727–18732.
  • 15
    Marquez JA, Smith CI, Petoukhov MV, Lo Surdo P, Mattsson PT, Knekt M, Westlund A, Scheffzek K, Saraste M, Svergun DI ( 2003) Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering. EMBO J 22: 4616–4624.
  • 16
    Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T ( 2005) The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13: 861–871.
  • 17
    Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE ( 2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66: 5790–5797.
  • 18
    Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J ( 2009) Crystal Structures of the Lyn protein tyrosine kinase domain in its apo- and inhibitor-bound state. J Biol Chem 284: 284–291.
  • 19
    Getlik M, Grutter C, Simard JR, Kluter S, Rabiller M, Rode HB, Robubi A, Rauh D ( 2009) Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem 52: 3915–3926.
  • 20
    Holm L, Kaariainen S, Rosenstrom P, Schenkel A ( 2008) Searching protein structure databases with DaliLite v.3. Bioinformatics 24: 2780–2781.
  • 21
    Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, Fluckiger AC, Witte ON, Kinet JP ( 1996) Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 271: 822–825.
  • 22
    Dinh M, Grunberger D, Ho H, Tsing SY, Shaw D, Lee S, Barnett J, Hill RJ, Swinney DC, Bradshaw JM ( 2007) Activation mechanism and steady state kinetics of Bruton's tyrosine kinase. J Biol Chem 282: 8768–8776.
  • 23
    Guo S, Wahl MI, Witte ON ( 2006) Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families. Int Immunol 18: 79–87.
  • 24
    Xu W, Doshi A, Lei M, Eck MJ, Harrison SC ( 1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3: 629–638.
  • 25
    Lin L, Czerwinski R, Kelleher K, Siegel MM, Wu P, Kriz R, Aulabaugh A, Stahl M (in press) Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity. Biochemistry.
  • 26
    Gill SC, von Hippel PH ( 1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 182: 319–326.
  • 27
    Otwinowski Z, Minor W ( 1997) Processing of X-ray diffraction data collected in oscillation mode. Macromolecular Crystallography (Part A) 276: 307–326.
  • 28
    Vagin A, Teplyakov A ( 2000) An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr 56: 1622–1624.
    Direct Link:
  • 29
    Murshudov GN, Vagin AA, Dodson EJ ( 1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240–255.
    Direct Link:
  • 30
    Emsley P, Cowtan K ( 2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
    Direct Link:
View Full Article (HTML) Get PDF (497K)